Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19

Not Applicable

Completed

• Conditions: Vaccine Refusal; Covid19

• Registration Number: NCT04871776
• Lead Sponsor: Brigham and Women's Hospital

Brief Summary

This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-30
• Study First Submitted QC: 2021-04-30
• Study First Posted: 2021-05-04
• Study Start: 2022-02-18
• Primary Completion: 2022-05-27
• Study Completion: 2022-08-17
• Results First Submitted: 2023-05-05
• Status Verified: 2023-12
• Results First Submitted QC: 2023-12-22
• Last Update Submitted: 2023-12-22
• Results First Posted: 2024-01-16
• Last Update Posted: 2024-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3671

Inclusion Criteria

• Patients in the Mass General Brigham system
• Aged 18 and older
• Are eligible for the COVID booster vaccine but have not received a dose at time of upcoming primary care clinic visit

Exclusion Criteria

• Documented allergy to a COVID vaccine or its components
• Home address outside of Massachusetts
• Did not receive full set of primary COVID-19 vaccination series

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of Participants Who Received a Booster Vaccination Through the Targeted Visit	2-5 days	Number of participants who received one dose of a COVID booster vaccine between randomization through the date of the scheduled visit, determined through electronic health records.

Secondary Outcome Measures

Name	Time	Method
Number of Participants Who Received a Booster Vaccination Within 6 Weeks of the Targeted Visit	6 weeks after the target visit	Number of participants who received one dose of a COVID booster vaccine between randomization through 6 weeks after the targeted visit, determined through electronic health records.

Trial Locations

Locations (1)

Mass General Brigham; 🇺🇸 Boston, Massachusetts, United States